Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you

Medicilon 20th.webp

In 2024, Medicilon will celebrate its 20th anniversary. At the time of departure, Medicilon shouldered the dream of China's new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream. During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO.

From chemical drugs to bi/multi-specific antibodies, ADCs, nucleic acids, mRNA, PROTAC, CGT and other fields, Medicilon continue to move towards the forefront of technology. From the initial provision of chemical services to one-stop biopharmaceutical preclinical R&D services, Medicilon continue to expand the services. From 0 to 420 IND approvals, Medicilon helps customers complete new drug clinical trial applications from China NMPA, US FDA, EU EMEA and Australia TGA. These include the world's first inhaled nanobody drug for the treatment of moderate to severe asthma, the world's first innovative drug targeting RNA helicase, the world's first dual-antibody ADC drug that completely knocks out fucose, the world's first CAR-raNK cell therapy, China's first ADC targeting folate receptor FRα, China's first potassium ion competitive acid blocker Keprasen tablets, China's first clinically approved STING agonist, China's first original highly selective EP4 receptor antagonist, China's first Muc1-ADC drug and more.

Medicilon collaborates with pharmaceutical companies to enable one-stop preclinical research and development of new drugs, collaborates with universities to promote in-depth integration of industry, academia and research, and collaborates with AI pharmaceutical companies to accelerate drug discovery and development. The Medicilon Academician Innovative Drug Maturation Center has established a new drug investment and financing support platform to provide financial support for new drug research and development. Furthermore, Medicilon has established a new drug research and development trading platform to facilitate the transformation and trading of new drug research and development stage results, thereby building a new drug empowerment ecosystem and promoting the integration and orderly development of industry, academia, research and finance. This is the joining and companionship of fellows that gathers the strength to be at the forefront and the efforts and perseverance of fellows that drive China's biopharmaceutical to the world.

Medicilon is grateful for the era, grateful for exploration, and grateful for having you along the way.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客